TrialCancer chemotherapy and pharmacology2022

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.

Sukhmani K Padda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.